Autolus Therapeutics plc (AUTL): Total Assets
$589.07M
As of 2025-12-31
$493.23M
As of 2026-06-30
+6.3%
3-year compound annual growth
+14.9%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $589.07M | -24.7% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $782.73M | +108.5% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $375.38M | n/a | 2025-03-20, Balance as of period end |
| 2023-09-30 | $406.10M | n/a | 2024-03-21, Balance as of period end |
| 2023-06-30 | $450.99M | n/a | 2024-03-21, Balance as of period end |
| 2023-03-31 | $459.97M | n/a | 2024-03-21, Balance as of period end |
| 2022-12-31 | $490.27M | n/a | 2024-03-21, Balance as of period end |
| 2022-09-30 | $263.83M | n/a | 2024-03-21, Balance as of period end |
| 2022-06-30 | $313.98M | n/a | 2024-03-21, Balance as of period end |
| 2022-03-31 | $363.99M | n/a | 2024-03-21, Balance as of period end |
| 2021-12-31 | $405.56M | +37.8% | 2023-03-07, Balance as of period end |
| 2020-12-31 | $294.24M | -3.1% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $303.53M | +19.4% | 2021-03-04, Balance as of period end |
| 2018-12-31 | $254.21M | n/a | 2020-03-03, Balance as of period end |
| 2018-09-30 | $273.20M | n/a | 2019-02-25, Balance as of period end |
| 2017-12-31 | $142.72M | n/a | 2019-02-25, Balance as of period end |
| 2017-09-30 | $148.66M | n/a | 2019-02-25, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $589.07M | -24.7% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $1.47B | +1.8% |
| Compugen Ltd (CGEN) | 2025-12-31 | $156.57M | +36.2% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $143.01M | +16.6% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $244.43M | -9.4% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $1.00B | -28.3% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $566.71M | +1.1% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $26.99M | -16.6% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $173.83M | -55.1% |
Compare AUTL, RXRX, CGEN, BDTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗